Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that it has entered into a collaboration, exclusive option and license agreement with AstraZeneca to develop, manufacture and commercialise autologous, engineered Treg cell therapies for two autoimmune disease indications.

Quell combines expertise from six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases. It achieved the biggest ever Series A investment in the field, with an initial financing round in March 2019 that was extended in February 2021 which brought total investment to $84m.

Tanel Ozdemir, Investor UCL Technology Fund said: “This is another fantastic achievement by the Quell team and well done to all involved. AstraZeneca is a world-leading partner and this collaboration is a major step forward in the engineered Treg field. We are now on the cusp of entering the clinic and look forward with excitement to proving the transformative potential of Quell’s platform.”

Further information:

Quell Therapeutics

• Share